What happened: A UK study using animal models suggests that GLP-1 drugs like Ozempic and Wegovy could prevent 'no-reflow', a serious complication after heart attacks. These drugs may reduce tissue damage in patients recovering from heart attacks.
Why it matters:
- Could improve survival and recovery outcomes for up to 100,000 heart attack patients annually in the UK.
- Offers a potential new use for weight-loss medications beyond their current purpose.
MNN Take: This research highlights a promising avenue where existing weight-loss drugs might help prevent dangerous heart attack complications, though further human studies are needed to confirm effectiveness.
Sources: Guardian UK